Krishna Yeshwant - 09 Jun 2026 Form 4 Insider Report for Parabilis Medicines, Inc. (PBLS)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Jun 2026, 16:52:24 UTC
Prior SEC filing
28 Jul 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Teresa Jurgensen, Attorney-in-Fact

Key filing fact

Krishna Yeshwant filed Form 4 for Parabilis Medicines, Inc. (PBLS) on 11 Jun 2026.

Key facts

  • This page summarizes Krishna Yeshwant's Form 4 filing for Parabilis Medicines, Inc. (PBLS).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 11 Jun 2026, 16:52.

Change

  • Previous filing in this sequence was filed on 28 Jul 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001585001 Primary reporting owner

Yeshwant Krishna

Relationship
Director
Address
C/O PARABILIS MEDICINES, INC., 30 ACORN PARK DRIVE, 6TH FLOOR, CAMBRIDGE
Signature
/s/ Teresa Jurgensen, Attorney-in-Fact
Signature date
11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PBLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+20,215
Change %
Price
$0.000000*
Shares after
20,215
Date
09 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,215
Exercise price
$20.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .